Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
作者信息
Mantero Vittorio, Baroncini Damiano, Balgera Roberto, Guaschino Clara, Basilico Paola, Annovazzi Pietro, Zaffaroni Mauro, Salmaggi Andrea, Cordano Christian
机构信息
Department of Neurology, MS Center, ASST Lecco, Via dell'Eremo 9/11, 23900, Lecco, Italy.
MS Center, Gallarate Hospital, ASST Valle Olona, Gallarate, Italy.
出版信息
J Neurol. 2021 Jun;268(6):2029-2030. doi: 10.1007/s00415-020-10196-9. Epub 2020 Aug 31.
Abstract
摘要
相似文献
1
Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
J Neurol. 2021 Jun;268(6):2029-2030. doi: 10.1007/s00415-020-10196-9. Epub 2020 Aug 31.
2
COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
Mult Scler Relat Disord. 2021 Aug;53:103049. doi: 10.1016/j.msard.2021.103049. Epub 2021 May 30.
3
Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
Expert Rev Clin Immunol. 2015 Feb;11(2):181-94. doi: 10.1586/1744666X.2015.993611. Epub 2014 Dec 16.
4
Rebound syndrome in two cases of MS patients after teriflunomide cessation.
Acta Neurol Belg. 2022 Oct;122(5):1381-1384. doi: 10.1007/s13760-022-01929-w. Epub 2022 Jul 8.
5
Chronic necrotizing aspergillosis: A new risk with teriflunomide in multiple sclerosis patients?
Rev Neurol (Paris). 2022 Mar;178(3):266-267. doi: 10.1016/j.neurol.2021.06.012. Epub 2021 Sep 24.
6
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Mult Scler. 2015 Oct;21(11):1476-7. doi: 10.1177/1352458515596601. Epub 2015 Jul 21.
7
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.
Mult Scler Relat Disord. 2021 Feb;48:102734. doi: 10.1016/j.msard.2020.102734. Epub 2021 Jan 2.
8
Palmar pustular psoriasis associated with teriflunomide treatment.
Mult Scler Relat Disord. 2019 Jan;27:400-402. doi: 10.1016/j.msard.2018.11.020. Epub 2018 Nov 19.
9
A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Mult Scler Relat Disord. 2017 Oct;17:92-94. doi: 10.1016/j.msard.2017.07.001. Epub 2017 Jul 3.
10
Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
Mult Scler. 2018 Sep;24(10):1383-1385. doi: 10.1177/1352458518761185. Epub 2018 Feb 23.
引用本文的文献
1
Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes.
J Immunol Sci. 2023;7(1):9-27. doi: 10.29245/2578-3009/2023/1.1241. Epub 2023 Jan 20.
2
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot.
Vaccines (Basel). 2022 Feb 21;10(2):341. doi: 10.3390/vaccines10020341.
3
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.
Vaccines (Basel). 2022 Feb 11;10(2):279. doi: 10.3390/vaccines10020279.
4
Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Front Immunol. 2021 Oct 5;12:730342. doi: 10.3389/fimmu.2021.730342. eCollection 2021.
5
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
6
The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China.
Front Neurol. 2021 May 28;12:682729. doi: 10.3389/fneur.2021.682729. eCollection 2021.
7
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Eur J Pharmacol. 2021 Sep 5;906:174233. doi: 10.1016/j.ejphar.2021.174233. Epub 2021 Jun 7.
8
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
J Neurol. 2021 Nov;268(11):3961-3968. doi: 10.1007/s00415-021-10545-2. Epub 2021 Apr 12.
9
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.
Curr Neuropharmacol. 2022;20(1):107-125. doi: 10.2174/1570159X19666210330094017.
10
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes.
Best Pract Res Clin Rheumatol. 2021 Mar;35(1):101657. doi: 10.1016/j.berh.2020.101657. Epub 2020 Dec 23.
本文引用的文献
1
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Clin Rheumatol. 2020 Sep;39(9):2797-2802. doi: 10.1007/s10067-020-05234-w. Epub 2020 Jun 19.
2
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
Mult Scler Relat Disord. 2020 Sep;44:102250. doi: 10.1016/j.msard.2020.102250. Epub 2020 Jun 3.
3
Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
Mult Scler. 2020 Sep;26(10):1268-1269. doi: 10.1177/1352458520926459. Epub 2020 May 28.
4
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
5
An Italian programme for COVID-19 infection in multiple sclerosis.
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
6
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
7
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2.
8
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365.
9
Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation.
Front Immunol. 2015 Oct 19;6:520. doi: 10.3389/fimmu.2015.00520. eCollection 2015.
10
Characterization of procollagen type IV and of its heterogenous accumulation products in the extracellular matrix of bovine lens cells in culture.
Int J Biochem. 1981;13(1):63-70. doi: 10.1016/0020-711x(81)90137-3.
Zotero 插件